A TB-500 10 mg label means the vial is supposed to contain 10 milligrams of peptide in total. It does not mean 10 mg per injection, and it does not tell you the concentration until the finished liquid volume is known. Most important, the number alone cannot prove that a vial bought from an anonymous seller contains TB-500 at all.
For a prescription vial, the usable answer comes from three pieces together: total mass, concentration, and the directions written for that specific formulation. The prescriber and dispensing pharmacy do that math. A copied online chart does not.
What TB-500 10 mg actually means
Milligrams measure mass: how much peptide is in the whole vial. A vial marked 5 mg is meant to hold half the total peptide mass of one marked 10 mg. That comparison says nothing yet about how much belongs in one injection.
Many peptide vials begin as lyophilized powder, meaning the peptide has been freeze-dried. Reconstitution means adding the specific sterile liquid named by the pharmacy. Only after the finished volume is known can the label state a concentration, the amount of peptide in each milliliter.
Those three numbers answer different questions:
| Label item | What it tells you | What it does not tell you |
|---|---|---|
| 10 mg | Intended total peptide mass in the vial | The amount for one injection |
| Finished volume in mL | How much liquid is in the vial | How much peptide is in each draw by itself |
| Concentration in mg/mL | Peptide mass in each milliliter | Whether that amount fits a particular person |
| Prescription directions | The measured amount and schedule for that patient | A reusable plan for someone else |
Why 5 mg and 10 mg are not dose choices
A larger vial can mean more days of the same prescribed amount, a different concentration, or a different formulation. It does not automatically mean a larger injection. Two vials with the same total mass can also produce different concentrations if their finished volumes differ.
That is why the vial-size question stops before dose selection. The separate guide to BPC-157 and TB-500 dosage explains what the evidence does and does not establish. The short answer here is simpler: the pharmacy label and prescription govern the amount, not the biggest number printed on the vial.
TB-500 is not the whole thymosin beta-4 protein
The name can create a second kind of mix-up. TB-500 is generally identified as Ac-LKKTETQ, a synthetic seven-amino-acid fragment of the 43-amino-acid protein thymosin beta-4. A 2012 analytical study used mass spectrometry, a laboratory method that identifies molecules by mass, to identify that acetylated fragment in a product called TB-500 (Esposito et al., Drug Testing and Analysis 2012).
So a label that says "10 mg thymosin beta-4" is not necessarily describing the same molecule as "10 mg TB-500." The full explanation of thymosin beta-4 and its fragment covers that evidence boundary. For vial reading, the practical point is to look for the exact drug name and form, not just the number.
One peptide and a blend are different labels
A single-compound TB-500 vial carries one peptide. Wolverine is a compounded blend of BPC-157 and TB-500 in the same vial. In any fixed-ratio blend, one draw contains both ingredients in the ratio prepared by the pharmacy.
That makes ingredient-level labeling essential. "10 mg total" is not the same statement as "10 mg TB-500," and neither phrase reveals the amount of the other peptide in a blend. The prescription and pharmacy label should name each ingredient and the finished concentration rather than leaving the patient to reverse-engineer it.
Why a gray-market 10 mg label proves very little
A seller can print a peptide name and a mass on a vial. That ink does not establish identity, purity, potency, or sterility. It also does not show whether "TB-500" means the seven-amino-acid fragment, an acetate form, or full-length thymosin beta-4.
This is not just a theoretical worry. A peer-reviewed laboratory analysis of products sold online as TB500 and TB1000 found that their contents were not consistently aligned with their earlier descriptions (Delcourt et al., Drug Testing and Analysis 2023). That study does not prove every online vial is wrong. It proves that a product name and a milligram claim cannot substitute for testing and traceability.
What a pharmacy-labeled vial adds
A pharmacy label is useful because it connects the container to a named prescription and a reachable licensed dispenser. It should make the practical details answerable: the exact drug and form, finished concentration, prescribed directions, storage conditions, lot traceability, and beyond-use date, the pharmacy-set date after which that preparation should not be used.
Behind the label, a Certificate of Analysis is a laboratory document used to check the bulk ingredient's identity and quality. FDA's explanation of bulk substances used in patient-specific compounding says the bulk substance must come with a valid certificate and be made by an FDA-registered establishment when the federal conditions apply. Registration does not turn the finished preparation into an approved product, but it creates a record that an anonymous vial lacks.
What changed in the July 2026 FDA review
As of September 9, 2026, the day this article was written, the newest relevant U.S. development was FDA's July 23–24 Pharmacy Compounding Advisory Committee review of TB-500-related bulk drug substances. In the briefing document prepared for that meeting, FDA said it had not identified any clinical studies or human-exposure data for TB-500 by any route. The agency also described inconsistent naming and gaps in publicly available tests for impurities, aggregates, microbiological quality, and bacterial endotoxin.
That review was about whether TB-500 free base and TB-500 acetate belong on a federal compounding list. It did not establish a human dose, validate a 5 mg or 10 mg retail vial, or erase the difference between TB-500 and full-length thymosin beta-4.
TB-500 has never had a U.S. FDA-approved product, and the compounded formulation offered here is not FDA-approved. Regulatory status is one factor in care, not a marketing gate: a licensed provider may still prescribe a compounded formulation, and that decision is between you and your doctor. At Promise, a licensed provider reviews every request and not everyone qualifies.
When the label and the plan do not match
A mismatch is a reason to pause and ask the dispensing pharmacy, not a reason to improvise. Useful questions include whether the milligrams refer to one ingredient or the whole blend, whether the concentration is stated before or after reconstitution, and which line contains the patient-specific amount. The pharmacy and reviewing provider can reconcile those records without guessing.
Competitive athletes have one more label to read. The 2026 World Anti-Doping Agency list places thymosin beta-4 and its derivatives, including TB-500, in class S2.3 and marks that class prohibited at all times, both in and out of competition. A prescription does not remove that anti-doping rule.
In the end, vial size is bookkeeping. The meaningful safeguards are the exact molecule, a verified pharmacy source, a label tied to the prescription, and a clinical plan that matches all three.